Citigroup set a $74.00 price objective on Intercept Pharmaceuticals (NASDAQ:ICPT) in a report issued on Thursday morning. The firm currently has a hold rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on ICPT. Wedbush restated an outperform rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 25th. Royal Bank of Canada increased their target price on Intercept Pharmaceuticals from $200.00 to $244.00 and gave the stock an outperform rating in a research report on Tuesday, September 26th. Needham & Company LLC reiterated a hold rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Jefferies Group reiterated a buy rating and set a $135.00 target price (down previously from $275.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Finally, Credit Suisse Group reiterated an outperform rating and set a $201.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 26th. Four analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $141.58.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $62.78 on Thursday. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $1,567.37, a PE ratio of -4.24 and a beta of -2.08. Intercept Pharmaceuticals has a 1 year low of $54.98 and a 1 year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.48) by $0.59. The business had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s quarterly revenue was up 697.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($3.59) earnings per share. sell-side analysts expect that Intercept Pharmaceuticals will post -13.35 EPS for the current year.

In related news, CEO Mark Pruzanski sold 1,532 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last three months, insiders have sold 2,566 shares of company stock valued at $151,025. 9.20% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of ICPT. WFG Advisors LP lifted its stake in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Intercept Pharmaceuticals by 90.9% during the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,182 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter worth approximately $212,000. SG Americas Securities LLC bought a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter worth approximately $235,000. Finally, QCM Cayman Ltd. bought a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter worth approximately $237,000. 73.76% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2017/12/25/citigroup-analysts-give-intercept-pharmaceuticals-icpt-a-74-00-price-target.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.